^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ontuxizumab (MORAb-004)

    i
    Other names: MORAb-004, MORAb 004
    Associations

    News

    Trials
    Company:
    Eisai
    Drug class:
    Endosialin inhibitor
    Associations

    News

    Trials
    4years
    Endosialin/CD248 may be a potential therapeutic target to prevent the invasion and metastasis in osteosarcoma. (PubMed, Oncol Lett)
    Taken together, these results suggest that endosialin may play a role in migration, and may be involved in the metastatic process of OSs. Furthermore, MORAb-004 reduces the motility of OS cells, and suppresses invasion and the development of metastatic lesions.
    Journal
    |
    FN1 (Fibronectin 1)
    |
    ontuxizumab (MORAb-004)